We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Oxidized Cellulose hEmostAsis evaluatioN (OCEAN)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: July 10, 2012
Last Update Posted: January 24, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Baxter Innovations GmbH
Information provided by (Responsible Party):
Baxter Healthcare Corporation
July 6, 2012
July 10, 2012
January 24, 2013
May 2012
November 2012   (Final data collection date for primary outcome measure)
Occurrence of adverse events (AEs)/ adverse device effects (ADEs) [ Time Frame: ≤30 ± 5 days/ end-of-study visit after device application ]
Occurrence of adverse events (AEs)/ adverse device effects (ADEs) up to 30 ± 5 days/ end-of-study visit after device application.
Same as current
Complete list of historical versions of study NCT01637025 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Oxidized Cellulose hEmostAsis evaluatioN
A Prospective, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of Traumastem as an Adjunct to Hemostasis for Tissue Bleeding in Open Cardiac, Intra-abdominal (Including Retroperitoneal) and Pelvic Surgery
The purpose of this study is to evaluate the safety and effectiveness of Traumastem to help stop bleeding in participants undergoing open cardiac, intra-abdominal (including retroperitoneal) and pelvic surgery as compared to Surgicel® Original (Surgicel; in some countries marketed as Tabotamp®)
Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Intra-operative Bleeding
  • Device: Oxidized cellulose strip
    Single use, intra-operative application to the target bleeding site
  • Device: Oxidized regenerated cellulose strip
    A substance used to promote hemostasis (stops bleeding) based on oxidized regenerated cellulose
    Other Name: Tabotamp®
  • Experimental: Traumastem - oxidized cellulose strip
    Intervention: Device: Oxidized cellulose strip
  • Active Comparator: Surgicel® Original - oxidized regenerated cellulose strip
    Intervention: Device: Oxidized regenerated cellulose strip
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
November 2012
November 2012   (Final data collection date for primary outcome measure)


  1. Participants and/or legal representative has/have provided signed informed consent. An assent form should be signed by Participants less than 18 years of age, if possible;
  2. Participants undergoing planned (non-emergency) open cardiac, intra-abdominal (including retroperitoneal) and pelvic surgery;
  3. Participants of childbearing potential present with a negative serum pregnancy test, and agree to employ adequate birth control measures for the duration of the study. Acceptable contraception methods are restricted to abstinence, barrier contraceptives, intrauterine contraceptive devices or licensed hormonal products;
  4. Participants are willing and able to comply with the requirements of the clinical investigation plan (CIP).


  5. Soft tissue, vascular/anastomotic or parenchymal bleeding is present after primary surgical hemostasis has been achieved. The TBS is defined as intra-operative bleeding where conventional methods for achieving hemostasis are ineffective (based on the type of tissue) or impractical (based on the location) and where treatment with topical hemostatic adjuncts such as Traumastem is deemed appropriate for use.


  1. Emergency surgery;
  2. Transplantation surgery;
  3. Minimally invasive surgery;
  4. Neurological and ophthalmological surgery;
  5. Major arterial bleeding at the target bleeding site (TBS);
  6. Major intra-operative complications that require resuscitation or deviation from the planned surgical procedure;
  7. Severe local inflammation at the operating field;
  8. Any prior radiation therapy to the operating field;
  9. Known severe congenital or acquired immunodeficiency (eg, human immunodeficiency virus [HIV] infection or long-term [> 3 months] treatment with immunosuppressive drugs);
  10. Known hypersensitivity to components of the investigational device;
  11. Participant is pregnant or lactating at the time of enrollment or becomes pregnant prior to the planned surgery. If the participant becomes pregnant during the 30 days following treatment exposure, attempts will be made to follow her through completion of the pregnancy. The investigator will record a narrative description of the course of the pregnancy and its outcome;
  12. Participant has a clinically significant medical, psychiatric, or cognitive illness, or drug/alcohol abuse that, in the opinion of the investigator, would affect participant's safety or compliance;
  13. Participant has participated in another clinical study involving an investigational device/drug within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an investigational device/drug during the course of this study.
Sexes Eligible for Study: All
Child, Adult, Senior
Contact information is only displayed when the study is recruiting subjects
Czech Republic,   Germany,   Hungary,   Poland
Not Provided
Not Provided
Not Provided
Baxter Healthcare Corporation
Baxter Healthcare Corporation
Baxter Innovations GmbH
Study Director: Edith Hantak, DVM Baxter Innovations GmbH
Baxter Healthcare Corporation
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP